This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Rye Brook, NY, Xylem Inc. is one of the leading providers of water solutions worldwide. The company is involved in the full water-process cycle, including collection, distribution and returning of water to the environment. It has significant presence in the United States, the Asia Pacific, Europe and various other nations. The company reports business operations under three segmental heads — Water Infrastructure, Sensus and Applied Water.
FLS vs. XYL: Which Stock Is the Better Value Option?
by Zacks Equity Research
FLS vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Stock Up 29.3% in 3 Months: What's Driving it?
by Zacks Equity Research
Xylem (XYL) stands to benefit from a solid backlog, new products, innovation, efforts to boost growth and focus on operational execution. However, its debt level remains high.
IDEX's Diversified Businesses & Buyouts to Aid Amid Pandemic
by Zacks Equity Research
IDEX's (IEX) diversified product offerings, presence in multiple markets, acquired assets and cost-saving measures might aid performances in the quarters ahead. The pandemic-led headwinds persist.
Why Is Xylem (XYL) Up 9.8% Since Last Earnings Report?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Xylem Displays Bright Prospects Amid Persistent Headwinds
by Zacks Equity Research
Xylem (XYL) to gain from a solid backlog, new products, innovation, efforts to boost growth and focus on operational execution. However, the pandemic-led challenges and high debt are concerning.
LXFR vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LXFR vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Surpasses Q2 Earnings Estimates, Provides View
by Zacks Equity Research
Xylem's (XYL) Q2 results reflect the adverse impacts of the pandemic, weak margins and forex woes. Sequential improvements are expected in organic sales and adjusted operating margin in Q3.
Xylem (XYL) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of 2.56% and 0.47%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Illinois Tool (ITW) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Illinois Tool (ITW) Q2 results are likely to reflect the pandemic impact, especially on automotive OEM businesses. Diversified businesses, enterprise strategy and cost-cutting might have aided.
Industrial Stock Q2 Earnings Due on Jul 30: SWK, XYL & More
by Avisekh Bhattacharjee
The impacts of the coronavirus outbreak, cost-related woes and other headwinds are expected to get reflected in the results of the majority of industrial stocks in Q2.
Xylem (XYL) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Xylem's (XYL) Q2 results are expected to reflect the adverse impacts of the pandemic on its operations. Solid contract wins, product offerings and cost-management are likely to have been tailwinds.
5 Industrial Stocks Poised for an Earnings Beat in Q2
by Payal Jalan
Industrial product stocks are expected to reflect gains from the pandemic-led product demand, spur in e-commerce and cost-saving measures. We present five stocks poised for an earnings beat in Q2.
Xylem (XYL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Xylem (XYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FLS vs. XYL: Which Stock Is the Better Value Option?
by Zacks Equity Research
FLS vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Provides Update on Q2 results, Confirms Deal Wins
by Zacks Equity Research
Xylem (XYL) provides a financial update for second-quarter results. Also, it secures two significant contracts in the second quarter.
LXFR vs. XYL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
LXFR vs. XYL: Which Stock Is the Better Value Option?
Xylem (XYL) Displays Bright Prospects Despite Headwinds
by Zacks Equity Research
Xylem (XYL) is likely to benefit from new products, innovation and focus on operational execution in the quarters ahead. However, soft end markets amid the coronavirus pandemic are concerning.
Xylem (XYL) Declines 19% YTD: What's Affecting the Stock?
by Zacks Equity Research
Xylem (XYL), with shares down 19% so far in 2020, faces risks from difficult end-market conditions due to the pandemic, forex woes and cost inflation. Q2 organic sales are likely to fall 20-30% y/y.
Why Is Xylem (XYL) Up 11.1% Since Last Earnings Report?
by Zacks Equity Research
Xylem (XYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Danaher's Stock Offering Proceeds to Fund Corporate Needs
by Zacks Equity Research
Danaher (DHR) completes the offering of common and convertible preferred shares. It intends on using the funds raised to pay for its corporate needs.
Xylem (XYL) Q1 Earnings Lag Estimates, Organic View Weak
by Zacks Equity Research
Xylem's (XYL) Q1 results reflect the adverse impacts of the coronavirus outbreak, a fall in margins and forex woes. Organic sales in Q2 are expected to reflect the uncertainties as well.
Xylem (XYL) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Xylem (XYL) delivered earnings and revenue surprises of -37.84% and -1.79%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Xylem (XYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Xylem's (XYL) Q1 results are expected to reflect the adverse impacts of the uncertainties caused by the coronavirus outbreak. But healthy balance sheet and cost actions might have aided.
Analysts Estimate Xylem (XYL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Xylem (XYL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How are Industrial Product Stocks Placed for Q1 Earnings?
by Payal Jalan
The coronavirus outbreak mars earnings and revenue prospects for many companies under the Industrial Products sector. Collective results for the first quarter of 2020 might be lackluster.